Cullinan Therapeutics, Inc.
CGEM
Updated: 24/09/2026, 15:14:27
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
No summaries found.
- Share price
- $16.87
- Market cap
- $1.04B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Nadim Ahmed
- Employees
- 109
- IPO date
- 08/01/2021
- Beta
- -0.01
- Last dividend
- $0.00
- Day range
- $16.78 – $21.61
- 52-week range
- $5.68 – $23.19
- 1-day performance
- -22.15%
- 1-year performance
- 197.01%
- Current drawdown (1Y)
- -27.25%
- CIK
- 0001789972
- CUSIP
- 230031106
- ISIN
- US2300311063
- Created
- 07/12/2025, 03:16:34
- Last update
- 24/09/2026, 15:14:27
Track Cullinan Therapeutics, Inc. with an AI analyst
See which prediction-market events move CGEM, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Cullinan Therapeutics: Heading Toward Paydirt
Seeking Alpha • STOCK • 11/06/2026, 13:41:04
Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases Transcript
Seeking Alpha • STOCK • 10/06/2026, 19:32:10
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
GlobeNewsWire • STOCK • 10/06/2026, 09:30:00
Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager
GlobeNewsWire • STOCK • 26/05/2026, 09:00:00
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
GlobeNewsWire • STOCK • 18/05/2026, 19:00:00
Cullinan Therapeutics: Cash-Rich With A Major 2027 FDA Catalyst
Seeking Alpha • STOCK • 30/04/2026, 15:53:50
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) Investment Analysis
Market Data • Market Data • 26/02/2026, 22:00:01
Cullinan Therapeutics: Thesis Strengthening For This T-Cell Engager Specialist
Seeking Alpha • STOCK • 23/02/2026, 18:39:15
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
GlobeNewsWire • STOCK • 18/02/2026, 08:00:00